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Strategy for intention to treat analysis in randomised
trials with missing outcome data
Loss to follow-up is often hard to avoid in randomised trials.This article suggests a framework for
intention to treat analysis that depends on making plausible assumptions about the missing data
and including all participants in sensitivity analyses
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The intention to treat principle requires all participants in a
clinicaltrialtobeincludedintheanalysisinthegroupstowhich
they were randomised, regardless of any departures from
randomised treatment.
1 This principle is a key defence against
bias, since participants who depart from randomised treatment
are usually a non-random subset whose exclusion can lead to
serious selection bias.
2
However, it is unclear how to apply the intention to treat
principle when investigators are unable to follow up all
randomisedparticipants.Fillingin(imputing)themissingvalues
isoftenseenastheonlyalternativetoomittingparticipantsfrom
theanalysis.
3Inparticular,imputingby“lastobservationcarried
forward” is widely used,
4 but this approach has serious
drawbacks.
3 For example, last observation carried forward was
appliedinarecenttrialofanoveldrugtreatmentinAlzheimer’s
disease.
5 The analysis was criticised because it effectively
assumed that loss to follow-up halts disease progression,
6 but
the authors argued that their analysis was in fact conservative.
7
Increasingly, trialists are expected to justify their handling of
missing data and not simply rely on techniques that have been
used in other clinical contexts.
8
To guide investigators dealing with these tricky issues, we
propose a four point framework for dealing with incomplete
observations (box). Our aim is not to describe specific methods
for analysing missing data, since these are described
elsewhere,
9 10 but to provide the framework within which
methods can be chosen and implemented. We argue that all
observed data should be included in the analysis, but undue
focusonincludingallrandomisedparticipantscanbeunhelpful
because participants with no post-randomisation data can
contribute to the results only through untestable assumptions.
The key issue is therefore not how to include all participants
butwhatassumptionsaboutthemissingdataaremostplausibly
correct,andhowtoperformappropriateanalysesbasedonthese
assumptions. We now expand on these four points.
Attempt to follow up all randomised
participants
Following up participants who withdraw from randomised
treatment can be difficult but is important because they may
differ systematically from those who remain on treatment. A
trial that does not attempt to follow participants after treatment
withdrawalcannotclaimtofollowtheintentiontotreatprinciple.
Perform a plausible main analysis
When data are incomplete, all statistical analyses make
untestable assumptions. The main analysis should be chosen to
be valid under a plausible assumption about the missing data.
For example, in the trial in Alzheimer’s disease, consider a
group of participants who are lost to follow-up between 6 and
12 months and a group of participants whose outcomes up to 6
months are similar to the first group’s but who are followed at
least to 12 months. It may be reasonable to assume in the main
analysis that these two groups have similar changes on average
from6to12months—a“missingatrandom”assumption,under
whichananalysisofallobservedoutcomedata,withadjustment
for selected covariates, is appropriate. A similar assumption
underlies standard analyses of time to event data.
Possible analysis methods under a “missing at random”
assumption include multiple imputation, inverse probability
weighting, and mixed models. These methods, and other
methods whose assumptions are less clear, are reviewed
elsewhere.
9 10
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1. Attempt to follow up all randomised participants, even if they withdraw from allocated treatment
2. Perform a main analysis of all observed data that are valid under a plausible assumption about the missing data
3. Perform sensitivity analyses to explore the effect of departures from the assumption made in the main analysis
4. Account for all randomised participants, at least in the sensitivity analyses
Assumptions about the missing data can often be supported by
collecting and reporting suitable information. For example,
“missing at random” is often plausible if the reason for most
missingdataisshowntobeadministrativeerrorbutimplausible
if the reason is undocumented disease progression.
Perform sensitivity analyses
Good sensitivity analyses directly explore the effect of
departures from the assumption made in the main analysis.
11
For example, if the main analysis assumes similarity between
groups who are and are not lost to follow-up, a good sensitivity
analysis might assume that the group who are lost to follow-up
have systematically worse outcomes. A clinically plausible
amountcouldbeaddedtoorsubtractedfromimputedoutcomes,
possibly using a technique such as multiple imputation.
9
Conversely, analysts could report how large an amount should
be added to or subtracted from imputed outcomes without
changing the clinical interpretation of the trial. With a small
proportion of missing binary outcomes, best and worst case
analyses may be appropriate.
12
Results of the sensitivity analyses should be concisely reported
in a paper’s abstract, saying, for example, whether the
significance of the main analysis was maintained in all
sensitivityanalysesorwaschangedinalimitedorlargenumber
of sensitivity analyses.
Account for all randomised participants
in the sensitivity analyses
When sensitivity analyses are carried out in this way, they
should account for all randomised participants. For example, if
a sensitivity analysis assumes a systematic difference between
missing and observed values, then its results directly depend
on the extent of missing data in the two trial arms.
Example of strategy in action
Weillustratetheproposedstrategyforintentiontotreatanalysis
using a recent trial comparing four doses of a new drug for
obesitywithtwocontrolgroups.
13Participantshadnineplanned
visits over 20 weeks. The trial report suggests that participants
who withdrew from trial treatment were followed up (point 1
of our proposed strategy). The primary analysis (point 2) used
last observation carried forward in a “modified intention to
treat” population that excluded three participants with no
post-randomisation measures. A sensitivity analysis used
repeated measures and thus assumed the data were missing at
random. Since the main analysis implicitly assumes that
participants neither gained nor lost weight on average after loss
to follow-up, more direct approaches to sensitivity analysis are
preferable. The figure⇓ shows our proposals for a hypothetical
participant who attends only four of the nine visits (solid line).
The red broken line shows the imputed value under last
observation carried forward, the study authors’ main analysis,
while the other lines show three sensitivity analyses (point 3):
sensitivity1showstheimputedvalueassumingthatparticipants
lost to follow-up returned to their baseline weight
14; sensitivity
2assumestheyregained50%oftheirlostweight;andsensitivity
3 assumes a larger fraction of the lost weight was regained in
theinterventiongroup.
15Participantswithnopost-randomisation
measurescouldbeincludedintheseanalysesbymakingsimilar
assumptions about their weight gain (point 4).
Discussion
The ideal solution to the problems discussed here is to avoid
missing data altogether. This is rarely practical, but missing
datacanbeminimisedbycarefuldesignandtrialmanagement,
10
and in particular by attempting to follow up all participants.
The obesity trial illustrated our strategy applied to a trial with
a repeatedly measured outcome. Analysis choices are more
limited in trials with a singly measured outcome. In trials with
timetoeventoutcomes,ananalysisthatincludesallrandomised
participants with censoring at the point of loss to follow-up is
generally acceptable, but possible biases from informative
censoring should be considered. In general, primary and
sensitivity analyses should be specified in detail, ideally in the
registered trial protocol and certainly before the unblinded data
are seen, as a defence against claims of data driven changes to
the analysis.
16
Someargueforconservativeanalyses.
17However,methodsthat
are conservative in some settings may not be conservative in
others. For example, last observation carried forward is often
claimed to be conservative, but it can be biased in favour of a
newtreatment.
18Wehaveinsteadsuggestedthatauthorsshould
maketheirmostplausibleassumptionsthebasisfortheirprimary
analysisandthenprovideconservatismbyassessingsensitivity
to departures from those assumptions.
Ourproposedanalysisstrategyconformstotheintentiontotreat
principle in the presence of missing outcomes and clarifies
uncertainty regarding its application. It acknowledges the
uncertainty introduced by missing data and therefore gives
investigators an added incentive to minimise the extent of
missingdata.
19Suchguidelinesareneededgiventheimportance
placedonintentiontotreatanalysesandtheubiquityofmissing
data in real world clinical trials.
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Fig 1 Possible ways to impute outcome measures at visit 9 for a hypothetical participant in the obesity trial who drops out
after visit 4: main analysis (last value brought forward) and three sensitivity analyses (1 assumes participants lost to follow-up
return to baseline weight; 2 assumes 50% of weight regained, and 3 assumes intervention group regains a greater proportion
of weight than controls)
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